Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petty, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petty, T. L.
(Chest. 2002;121:116S-120S.)
© 2002 American College of Chest Physicians

COPD in Perspective*

Thomas L. Petty, MD, Master FCCP

* From the University of Colorado Health Sciences Center, Denver, CO.

Correspondence to: Thomas L. Petty, MD, Master FCCP, 1850 High Street, Denver, CO 80218; e-mail: TLPdoc{at}aol.com

In the last 200 years or so, the recognition, diagnosis, and understanding of the pathogenesis of COPD have evolved considerably. Over the past few decades, various definitions of COPD and its "components" also have developed. Despite this, however, the treatment options for patients with this relentlessly progressive disorder are relatively limited. In the mid-19th century, the introduction of the spirometer yielded a powerful tool for the diagnosis of COPD. The currently available small, cheap spirometers hold great promise to help patients and their physicians closely monitor lung function. Early recognition of the close associations among emphysema and, more recently, small airways disease, and impaired airflow is discussed. This review also stresses the importance of the identification of COPD in its initial stages and the early onset of appropriate treatment. The therapy for COPD has changed in the last 40 years. Drug therapies in the 1960s included potassium iodide and ephedrine. Corticosteroids were not used, and oxygen therapy and exercise were actually contraindicated. Modern therapy for COPD is now more systematic and includes the use of bronchodilators and corticosteroids to improve airflow, in addition to oxygen therapy, pulmonary rehabilitation and, in selected patients, lung volume reduction surgery. The causal link between the chronic inhalation of tobacco smoke and COPD is beyond doubt, and smoking cessation remains the most important goal for patients. It is hoped that new, more effective therapies will soon be available for the treatment of this disabling disorder to provide improvement in symptoms and patient quality of life and to reduce or stop the rate of disease progression and mortality in patients with COPD.

Key Words: chronic bronchitis • COPD • definition • emphysema • history • oxygen therapy




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
P. R. Reynolds, M. G. Cosio, and J. R. Hoidal
Cigarette Smoke-Induced Egr-1 Upregulates Proinflammatory Cytokines in Pulmonary Epithelial Cells
Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 314 - 319.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
R. Tomic, C. C. Lassiter, J. D. Ritzenthaler, H. N. Rivera, and J. Roman
Anti-Tissue Remodeling Effects of Corticosteroids: Fluticasone Propionate Inhibits Fibronectin Expression in Fibroblasts
Chest, January 1, 2005; 127(1): 257 - 265.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Chest Physicians.